Patents Examined by Robert Landsman
  • Small molecule polypeptide for inhibiting inflammation
    Patent number: 9688726
    Abstract: The present invention provides a polypeptide that is rich in leucine and used for preventing and restraining inflammation, and an application of same. The present invention further provides a method for preparing the polypeptide and a pharmaceutical composition containing the polypeptide. The advantage of the polypeptide comprises: small molecular weight, so as to permeate various eye tissue barriers; high water solubility, so as to have high dissolubility in neutral tears, aqueous humor and vitreous humor; and simple synthesis, so as to have a low preparation cost.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: June 27, 2017
    Assignees: Shanghai First People's Hospital
    Inventors: Xun Xu, Yan Xu
  • Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof
    Patent number: 9676833
    Abstract: Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffolds including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: June 13, 2017
    Assignee: Zyngenia, Inc.
    Inventors: Viktor Roschke, David Lafleur, David M. Hilbert, Peter Kiener
  • Targeted TGF? inhibitors
    Patent number: 9676863
    Abstract: This invention relates generally to bifunctional molecules including (a) a TGF?RII or fragment thereof capable of binding TGF? and (b) an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1), uses of such molecules (e.g., for treating cancer), and methods of making such molecules.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: June 13, 2017
    Assignee: Merck Patent GmbH
    Inventor: Kin-Ming Lo
  • cDNA-derived nucleic acids encoding red-shifted channelrhodopsins
    Patent number: 9676836
    Abstract: Methods and compositions are used to identify and characterize new channelrhodopsins derived from algae and several of which are red-shifted. The rhodopsin domain of these red-shifted channelrhodopsins can be cloned and expressed in mammalian systems and used in optogenetic applications and as therapeutic agents. Also provided are methods and compositions for use in red-shifting the absorbance maxima of channelrhodopsins in order to improve their utility for use in vivo.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: June 13, 2017
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: John Lee Spudich, Elena G. Govorunova, Oleg A. Sineshchekov
  • Pharmaceutical compositions comprising DENND1A variant 2 and methods of use thereof
    Patent number: 9676844
    Abstract: Pharmaceutical compositions and methods for the treatment of DENND1 A. V2 related disorders, such as PCOS, are provided. In particular, humanized and mouse monoclonal antibodies specific for DENND1 A. V2 and methods for using the same are provided.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: June 13, 2017
    Assignees: Virginia Commonwealth University, The Penn State Research Foundation
    Inventors: Janette M. McAllister, Jerome F. Strauss, Neil D. Christensen
  • In vitro method using hetero-oligomeric T1R1/T1R3 taste receptors to identify umami tastants
    Patent number: 9671390
    Abstract: The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. Also the present invention relates to the use of hetero-oligomeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: June 6, 2017
    Assignee: SENOMYX, INC.
    Inventors: Mark Zoller, Xiaodong Li, Lena Staszewski, Shawn O'Connell, Sergey Zozulya, Jon Elliot Alder, Hong Xu, Fernando Echeverri
  • Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders
    Patent number: 9669049
    Abstract: This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: June 6, 2017
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Derek G. Ostertag, Ryan S. Burnett, Amy H. Lin, Tiffany Huang, Joan M. Robbins
  • Method of inhibiting angiogenesis using inhibitors of G-protein-coupled receptor kinase interacting protein-1 (GIT1)
    Patent number: 9670259
    Abstract: The present invention is directed to methods and compositions comprising G-protein-coupled receptor kinase interacting protein-1 (GIT1) inhibitors that are suitable for inhibiting angiogenesis in a subject and treating related conditions.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 6, 2017
    Assignee: University of Rochester
    Inventors: Bradford C. Berk, Jinjiang Pang, Syamantak Majumder
  • Liquid formulations of long-acting interferon alpha conjugates
    Patent number: 9669105
    Abstract: Disclosed is a liquid formulation in which a long-acting INF? conjugate that has improved in vivo duration and stability can be stored stably for a long period of time. It comprises a stabilizer comprising a buffer, a sugar alcohol, a non-ionic surfactant and an isotonic agent. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting INF? conjugates.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: June 6, 2017
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Dae Seong Im, Jae Min Lee, Jong Soo Lee, Sung Min Bae, Se Chang Kwon
  • Oncostatin M receptor antigen binding proteins
    Patent number: 9663571
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins. e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: May 30, 2017
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • Methods of treating autoimmune diseases by administering monoclonal antibodies against human IL-12
    Patent number: 9657097
    Abstract: The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: May 23, 2017
    Assignee: Hoffman-LaRoche, Inc.
    Inventors: Maurice Kent Gately, David Howard Presky
  • Anti-glucagon antibodies
    Patent number: 9657099
    Abstract: The present invention provides antibodies that bind to glucagon and methods of using the same. According to certain embodiments, the antibodies of the invention bind human GCG with high affinity. The antibodies of the invention may be fully human antibodies. The antibodies of the invention are useful for the treatment of various diseases or disorders characterized by elevated blood glucose levels, as well as other GCG-related disorders.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: May 23, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Haruka Okamoto, Jesper Gromada
  • Methods for treating diseases with peptides that inhibit IGF-1
    Patent number: 9657080
    Abstract: The invention relates to peptides useful for inhibiting IGF-1 activity and their use as agents for inhibition of in vitro cell proliferation and for treatment of various diseases.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: May 23, 2017
    Assignee: Universite Pierre Et Marie Curie (Paris 6)
    Inventors: Claude Carelli, Zvi Laron, Gila Maor
  • Composition comprising a mixture of CD95-Fc isoforms
    Patent number: 9657083
    Abstract: The present invention relates to a composition comprising a mixture of fusion protein isoforms, each fusion protein comprising an extracellular CD95 domain or a functional fragment thereof or an Fc domain or functional fragment thereof, formulations providing such composition in a stable form as well as a method for producing such a composition.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: May 23, 2017
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Method of screening compounds for the treatment of diabetes
    Patent number: 9657348
    Abstract: A method of screening for a candidate compound for the treatment of a condition involving dysregulation of metabolism in a mammal, by bringing a compound into contact with cells that express a GPCR and that further express a GRK, determining whether the contacting causes a response of the GRK in cells brought into contact with the compound, determining whether the contacting causes a response of a classical secondary messenger in cells brought into contact with the compound; and identifying the candidate compound based on the determined GRK response and response of a classical secondary messenger in the cells. A kit for use in the method. A compound for use in the treatment of a condition involving dysregulation of metabolism in a mammal and a method of treatment of such a condition.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: May 23, 2017
    Assignee: ATROGI AB
    Inventor: Tore Bengtsson
  • Methods of preventing or treating mucositis by administering RLIP76
    Patent number: 9649353
    Abstract: Provided are compositions and methods for preventing or treating damage to mucosal tissue, for example as a result of radiation and/or chemotherapy. The damage may be, for example, oral or gastrointestinal mucositis.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: May 16, 2017
    Assignee: TERAPIO CORPORATION
    Inventor: Casey C. Cunningham
  • Epidermal growth factor receptor antibody
    Patent number: 9644031
    Abstract: Provided are an improved EGFR antibody or a functional segment thereof, comprising an engineered heavy chain and light chain. Specifically, the antibody is an engineered whole human-source monoclonal antibody. Also provided is a method for manufacturing said whole human-source antibody and usage of the antibody in the manufacture of medicines used for the treatment of tumors.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: May 9, 2017
    Assignees: GENRIX (SHANGHAI) BIOPHARMACERTICAL CO., LTD., BIOEX THERAPEUTICS INC.
    Inventors: Jie Liu, Zhuobing Zhang, Jikuan Shan, Wei Suo
  • Sublingual fentanyl spray
    Patent number: 9642844
    Abstract: The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable sale thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 9, 2017
    Assignee: INSYS DEVELOPMENT COMPANY, INC.
    Inventors: S. George Kottayil, Venkat R. Goskonda, Zhongyuan Zhu, Linet Kattookaran, Neha Parikh
  • Sublingual fentanyl spray and methods of use to treat pain
    Patent number: 9642797
    Abstract: The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: May 9, 2017
    Assignee: INSYS DEVELOPMENT COMPANY, INC.
    Inventors: S. George Kottayil, Venkat R. Goskonda, Zhongyuan Zhu, Linet Kattookaran, Neha Parikh
  • Monoclonal antibodies for detection of folate receptor 1
    Patent number: 9637547
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: May 2, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui